Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by GrahamBon Sep 11, 2024 9:00am
134 Views
Post# 36218222

Deja Vi

Deja Vi
This stock keeps drifting lower, over95% from peak, with dilution ongoing... Why???

After years and years of awaiting new versions of this product, stories of thousands of leads that are materializing 100% into sales,NICE guaranteed , Sales teams, China’s  sales, GE alliance and tens of thousands of distributors, once again the idea of putting these machines out into KL‘s is being put for. Meanwhile, the sales have never materialized always being in the order of 30 to 80,000 per year, on costs numbering in the millions.
 
The last financing still hasn’t closed, telling me that the street is not interested. Going now to retail investors to see if they can keep this going. We will see what happens waiting waiting waiting.
 
If this is the standard of care-why isn’t anyone ordering it and why isn’t the cardiology literature saying this?
Just being stated here by jopatchie and other promoters imo 
 
For the record ie. from Sedar:
 
Total revenue for year ending Dec. 31, 2018  = $60,177
Total revenue for year ending Dec. 31, 2019  = $81,023
Total revenue for year ending Dec. 31, 2020  = $36,017
 
Total revenue for year ending Dec. 31, 2021  = $Nil
Total revenue for year ending Dec. 31, 2022 68,167
 
Total revenue for year ending Dec. 31, 2023 
 
Revenue to date ~ 30000
 
All in my opinion, do your own due diligence. Don’t trust what you read on this board
<< Previous
Bullboard Posts
Next >>